Journal of Shandong University (Health Sciences) ›› 2021, Vol. 59 ›› Issue (9): 117-123.doi: 10.6040/j.issn.1671-7554.0.2021.0956

Previous Articles     Next Articles

Research progress of drug resistance in ovarian cancer and targeted therapy strategy

HA Chunfang1,2, LI Ruyue3   

  1. 1. Gynecology Department, General Hospital of Ningxia Medical University, Yinchuan 750004, Ningxia, China;
    2. Key Laboratory of Fertility Preservation and Maintenance of Ministry of Education, Yinchuan 750004, Ningxia, China;
    3. Ningxia Medical University, Yinchuan 750004, Ningxia, China
  • Published:2021-10-15

RichHTML

40

PDF (PC)

1680

Abstract: Cytoreductive surgery combined with chemotherapy is the major treatment of Epithelial ovarian cancer(EOC). The application of no residual disease(R0)targeted ovarian cancer debulking with individualized chemotherapy has greatly improved the five-year survival rates. However, the drug resistance and recurrence of advanced patients are still a difficult problem for clinicians and researchers in this field. Chemotherapy resistance is a hot and difficult spot to be solved urgently due to unclear etiology and complex mechanism. In recent years, the basic and clinical researches on the mechanism of drug resistance in ovarian cancer mainly include drug transport, drug metabolism, apoptosis, DNA damage repair and epigenetic changes. And some studies have shown that autophagy, altered metabolism, tumor microenvironment and tumor stem cells also have played an important role in drug resistance in ovarian cancer. The strategy targeting these mechanisms has provided a new method to increase sensitivity to chemotherapy and improve the prognosis.

Key words: Ovarian cancer, Drug resistance, Mechanism, Targeted treatment

CLC Number: 

  • R737.31
[1] Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer[J]. Best Pract Res Clin Obstet Gynaecol, 2017, 41: 3-14. doi: 10.1016/j.bpobgyn.2016.08.006.
[2] Kalayda GV, Wagner CH, Jaehde U. Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells [J]. J Inorg Biochem, 2012, 116: 1-10. doi: 10.1016/j.jinorgbio.2012.07.010.
[3] Jandial DA, Brady WE, Howell SB, et al. A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: an NRG Oncology/Gynecologic Oncology Group study [J]. Gynecol Oncol, 2017, 145(2): 236-242.
[4] Lancaster CS, Sprowl JA, Walker AL, et al. Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics [J]. Mol Cancer Ther, 2013, 12(8): 1537-1544.
[5] Svoboda M, Wlcek K, Taferner B, et al. Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport [J]. Biomed Pharmacother, 2011, 65(6): 417-426.
[6] Tong X, Zhao J, Zhang Y, et al. Expression levels of MRP1, GST-π, and GSK3β in ovarian cancer and the relationship with drug resistance and prognosis of patients [J]. Oncol Lett, 2019, 18(1): 22-28.
[7] Guo W, Dong W, Li M, et al. Mitochondria P-glycoprotein confers paclitaxel resistance on ovarian cancer cells [J]. Onco Targets Ther, 2019, 12: 3881-3891. doi: 10.2147/OTT.S193433.
[8] Gao B, Yang F, Chen W, et al. Multidrug resistance affects the prognosis of primary epithelial ovarian cancer [J]. Oncol Lett, 2019, 18(4): 4262-4269.
[9] Zhao MD, Li JQ, Chen FY, et al. Co-delivery of curcumin and paclitaxel by “core-shell” targeting amphiphilic copolymer to reverse resistance in the treatment of ovarian cancer [J]. Int J Nanomedicine, 2019, 14: 9453-9467. doi: 10.2147/IJN.S224579.
[10] Dobiasová S, Reho rová K, Ku cerová D, et al. Multidrug resistance modulation activity of silybin derivatives and their anti-inflammatory potential [J]. Antioxidants(Basel), 2020, 9(5): 455. doi: 10.3390/antiox9050455.
[11] Kawahara B, Ramadoss S, Chaudhuri G, et al. Carbon monoxide sensitizes cisplatin-resistant ovarian cancer cell lines toward cisplatin via attenuation of levels of glutathione and nuclear metallothionein [J]. J Inorg Biochem, 2019, 191: 29-39. doi: 10.1016/j.jinorgbio.2018.11.003.
[12] DeLoia JA, Zamboni WC, Jones JM, et al. Expression and activity of taxane-metabolizing enzymes in ovarian tumors [J]. Gynecol Oncol, 2008, 108(2): 355-360.
[13] van Eijk M, Boosman RJ, Schinkel AH, et al. Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes [J]. Cancer Chemother Pharmacol, 2019, 84(3): 487-499.
[14] Yuan J, Lan H, Jiang X, et al. Bcl2 family: novel insight into individualized therapy for ovarian cancer(Review)[J]. Int J Mol Med, 2020, 46(4): 1255-1265.
[15] Zhang Y, Huang F, Luo Q, et al. Inhibition of XIAP increases carboplatin sensitivity in ovarian cancer [J]. Onco Targets Ther, 2018, 11: 8751-8759. doi: 10.2147/OTT.S171053.
[16] Li RH, Yue C, Wei BB, et al. [In vivo study of siRNA silencing XIAP gene to reverse taxol-resistance in human ovarian cancer cells] [J]. Sichuan Da Xue Xue Bao Yi Xue Ban, 2020, 51(3): 320-324.
[17] Usman RM, Razzaq F, Akbar A, et al. Role and mechanism of autophagy-regulating factors in tumorigenesis and drug resistance [J]. Asia Pac J Clin Oncol, 2021, 17(3): 193-208.
[18] Luan W, Pang Y, Li R, et al. Akt/mTOR-mediated autophagy confers resistance to BET inhibitor JQ1 in ovarian cancer [J]. Onco Targets The, 2019, 12: 8063-8074. doi: 10.2147/OTT.S220267.
[19] Tan WX, Xu TM, Zhou ZL, et al. TRP14 promotes resistance to cisplatin by inducing autophagy in ovarian cancer [J]. Oncol Rep, 2019, 42(4): 1343-1354.
[20] Wang J, Wu GS. Role of autophagy in cisplatin resistance in ovarian cancer cells [J]. J Biol Chem, 2014, 289(24): 17163-17173.
[21] Amaravadi RK, Kimmelman AC, Debnath J. Targeting autophagy in cancer: recent advances and future directions [J]. Cancer Discov, 2019, 9(9): 1167-1181.
[22] Dar S, Chhina J, Mert I, et al. Bioenergetic adaptations in chemoresistant ovarian cancer cells [J]. Sci Rep, 2017, 7(1): 8760. doi: 10.1038/s41598-017-09206-0.
[23] Han CY, Patten DA, Lee SG, et al. p53 Promotes chemoresponsiveness by regulating hexokinase II gene transcription and metabolic reprogramming in epithelial ovarian cancer [J]. Mol Carcinog, 2019, 58(11): 2161-2174.
[24] Bauerschlag DO, Maass N, Leonhardt P, et al. Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer [J]. J Transl Med, 2015, 13: 146. doi: 10.1186/s12967-015-0511-3.
[25] Papaevangelou E, Almeida GS, Box C, et al. The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model [J]. Int J Cancer, 2018, 143(4): 992-1002.
[26] Criscuolo D, Avolio R, Calice G, et al. Cholesterol homeostasis modulates platinum sensitivity in human ovarian cancer [J]. Cells, 2020, 9(4): 828. doi: 10.3390/cells9040828.
[27] Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics [J]. Cell Death Dis, 2013, 4(3): e532. doi: 10.1038/cddis.2013.60.
[28] Hudson CD, Savadelis A, Nagaraj AB, et al. Altered glutamine metabolism in platinum resistant ovarian cancer [J]. Oncotarget, 2016, 7(27): 41637-41649.
[29] Masamha CP, LaFontaine P. Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy [J]. J Cell Biochem, 2018,119(7): 6136-6145.
[30] Schärer OD. Nucleotide excision repair in eukaryotes [J]. Cold Spring Harb Perspect Biol, 2013, 5(10): a012609. doi: 10.1101/cshperspect.a012609.
[31] Hassan M, Watari H, AbuAlmaaty A, et al. Apoptosis and molecular targeting therapy in cancer [J]. Biomed Res Int, 2014, 2014: 150845. doi: 10.1155/2014/150845.
[32] Guo J, Jin D, Wu Y, et al. Retraction notice to ‘The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells’ [EBioMedicine 35(2018)204-221] [J]. EBioMedicine, 2021, 63: 103168. doi: 10.1016/j.ebiom.2020.103168.
[33] Bogush TA, Popova AS, Dudko EA, et al. ERCC1 as a marker of ovarian cancer resistance to platinum drugs[J]. Antibiot Khimioter, 2015, 60(3-4): 42-50.
[34] Stefansson OA, Villanueva A, Vidal A, et al. BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer [J]. Epigenetics, 2012, 7(11): 1225-1229.
[35] Patch AM, Christie EL, Etemadmoghadam D, et al. Whole-genome characterization of chemoresistant ovarian cancer [J]. Nature, 2015, 521(7553): 489-494.
[36] Wong-Brown MW, van der Westhuizen A, Bowden NA. Targeting DNA repair in ovarian cancer treatment resistance [J]. Clin Oncol(R Coll Radiol), 2020, 32(8): 518-526.
[37] Ali MW, Cacan E, Liu Y, et al. Transcriptional suppression, DNA methylation, and histone deacetylation of the regulator of G-protein signaling 10(RGS10)gene in ovarian cancer cells [J]. PLoS One, 2013, 8(3): e60185. doi: 10.1371/journal.pone.0060185.
[38] Zeller C, Brown R. Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer [J]. Ther Adv Med Oncol, 2010, 2(5): 319-329.
[39] Moufarrij S, Dandapani M, Arthofer E, et al. Epigenetic therapy for ovarian cancer: promise and progress [J]. Clin Epigenetics, 2019, 11(1): 7. doi: 10.1186/s13148-018-0602-0.
[40] Mo L, Pospichalova V, Huang Z, et al. Ascites increases expression/function of multidrug resistance proteins in ovarian cancer cells [J]. PLoS One, 201, 10(7): e0131579. doi: 10.1371/journal.pone.0131579.
[41] Tang J, Zhu J, Ye Y, et al. Inhibition LC3B can increase chemosensitivity of ovarian cancer cells [J]. Cancer Cell Int, 2019, 19: 199. doi: 10.1186/s12935-019-0921-z.
[42] Nowak M, Klink M. The role of tumor-associated macrophages in the progression and chemoresistance of ovarian cancer [J]. Cells, 2020, 9(5): 1299. doi: 10.3390/cells9051299.
[43] Zhang F, Cui JY, Gao HF, et al. Cancer-associated fibroblasts induce epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer via CXCL12/CXCR4 axis [J]. Future Oncol, 2020, 16(32): 2619-2633.
[44] Muñoz-Galván S, Carnero A. Targeting cancer stem cells to overcome therapy resistance in ovarian cancer [J]. Cells, 2020, 9(6): 1402. doi: 10.3390/cells9061402.
[45] Pieterse Z, Amaya-Padilla MA, Singomat T, et al. Ovarian cancer stem cells and their role in drug resistance [J]. Int J Biochem Cell Biol, 2019, 106: 117-126. doi: 10.1016/j.biocel.2018.11.012.
[46] Mihanfar A, Aghazadeh Attari J, Mohebbi I, et al. Ovarian cancer stem cell: a potential therapeutic target for overcoming multidrug resistance [J]. J Cell Physiol, 2019, 234(4): 3238-3253.
[47] Keyvani V, Farshchian M, Esmaeili SA, et al. Ovarian cancer stem cells and targeted therapy [J]. J Ovarian Res, 2019, 12(1): 120. doi: 10.1186/s13048-019-0588-z.
[1] GE Li-Juan, JIN Rui-Feng, WANG Ji-Wen, HU Xin-Sheng, LIKun. Association between the C1236T polymorphism in multi-drug resistance gene 1 and response to antiepileptic drug treatment in epileptic patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2209, 47(6): 99-102.
[2] YUAN Baowen, WANG Pei, HUANG Wei. Regulatory role of histone deacetylase SIRT1 in pancreatic cancer metabolism [J]. Journal of Shandong University (Health Sciences), 2022, 60(3): 1-12.
[3] LI Yan, LIU Jing, LI Juan, YANG Qiuhong. Clinical characteristics and placental pathology of bloodstream infection in 50 pregnant women [J]. Journal of Shandong University (Health Sciences), 2022, 60(1): 48-54.
[4] JU Jianhua, YANG Zhenye, LI Qinglian, HAN Yanan, LI Yanqing, QIAO Yijun, YANG Hu, ZHANG Huaran. Advances on drugs derived from microbial sources and future perspectives [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 43-50.
[5] GUO Man, LIU Peng, LONG Lin. Effect of Fangxian Decoction on rats with radiation pneumonia and its mechanism [J]. Journal of Shandong University (Health Sciences), 2021, 59(8): 53-60.
[6] XU Bing, LI Yong, LIU Ming, LIU Yonghui. Silencing PRRX1 gene expression enhances the sensitivity of prostate cancer resistant cell line PC-3/DTX to docetaxel [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 103-110.
[7] WANG Zhengyang, XIA Yan, SHI Kaixuan, TAO Kun, WANG Xiaojie. Effects of Trametinib on PAX8 expression in ovarian cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(10): 23-29.
[8] JIANG Xiaofeng, YAO Jingjing, ZHU Dawei, HE Ping, SHI Xuefeng, MENG Qingyue. Influence of compensation mechanism reform on the hospitalization expenses of a county-level public hospital in Shandong Province [J]. Journal of Shandong University (Health Sciences), 2020, 1(9): 95-102.
[9] FU Zhenmei, MA Mingze. Expression of P-glycoprotein in the colonic mucosa of ulcerative colitis patients and its clinical significance [J]. Journal of Shandong University (Health Sciences), 2020, 58(12): 54-59.
[10] WANG Baojin, ZHAO Xinxin, LI Xia, MA Qian, WANG Xinyue, SUN Yang, SHI Zhongna. miR-203 targeting Survivin to inhibit the proliferation, migration and invasion of ovarian cancer cells [J]. Journal of Shandong University (Health Sciences), 2020, 58(12): 23-28.
[11] ZHANG Ning, YANG Yan, LI Rui, YIN Yunhong, LI Hao, QU Yiqing. Analysis of risk factors and drug resistance of Acinetobacter baumannii in patients with chronic obstructive pulmonary disease [J]. Journal of Shandong University (Health Sciences), 2019, 57(9): 88-96.
[12] GAO Yuan, JI Wei, XIAO Dan, LIU Jing, PENG Danbing, JI Chun. Mechanism of anti-inflammatory effect for Astragali Complanati Semen based on network pharmacology [J]. Journal of Shandong University (Health Sciences), 2019, 57(9): 59-68.
[13] ZHANG Lu, XU Minxuan, YANG Xiaoxue, JIA Liying. An analysis of income compensation of public hospitals based on a quasi-experimental design ——a case study of a first-class hospital in Shandong Province [J]. Journal of Shandong University (Health Sciences), 2019, 57(3): 109-114.
[14] WANG Shixuan, ZHANG Jinjin. Advances in the mechanisms research and preventive measures of ovarian aging [J]. Journal of Shandong University (Health Sciences), 2019, 57(2): 16-22.
[15] GUAN Hongwei, LI Juan, SUN Rui, LIU Jie, LI Changzhong. Biological effects of ubenimex on ovarian cancer A2780 cell [J]. Journal of Shandong University (Health Sciences), 2019, 57(12): 46-51.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] WANG Huan-liang,SUN Bao-zhu,DU Hong-mei,ZHOU Chang-qing,ZHANG Li. Controlling the depth of propofol anesthesia using the bispectral indexand the systolic blood pressure[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2006, 44(5): 471 -474 .
[2] YU Hui1,2, CHEN Shaohua1, ZHAO Jiajun2, GAO Ling3
. Effects of ethanol on glycogen content, GSK3β，
and PAMPK of L02 cells[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(04): 75 -78 .
[3] HUANGQing,TIAN Hui,LI Lin,LIANG Fei,LIU Xi-xian. [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2006, 44(6): 556 -559 .
[4] ZHU Mei-jia,HAN Ju,WANG Xin-yi,LU Wei,WANG Ai-hua,GUAN Xin-hua,CAO Xia,CAO Bing-zhen. [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2006, 44(8): 834 -839 .
[5] SONG Hai-yan, WU Yu-ling, ZHANG Yan-ping. Protective effect of oyster extract on apoptotic cells in neural tube defect induced by hyperthermia[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(2): 113 -116 .
[6] SONG Yong-hong,MA Chun-hong,LV Hong-juan,ZHU Chuan-fu,NIE Xiang-min,WANG Mei,LIU Yan,ZHANG Ping. HLA allele polymorphism in northern Hans of China[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(6): 546 -553 .
[7] WANG Zhi-ang,DING Xua,SUN Peng/sup>,WANG Cheng-wei,HAO Xiao-guang,PAN Shun. Role of pre-operative cerebral angiography in cerebral artery stenosis stent angioplasty[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(2): 146 -148 .
[8] ZHAO Zheng-bin1， XUE Shuang-lin2， ZHANG Li-ting1， LI Jun-feng1，ZHAO Rong-rong1， ZHOU Hai-lian3， CHEN Hong1. Effects of procyanidins on the proliferation of hepatic stellate cells and production of TIMP-1 induced by leptin[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(7): 46 .
[9] ZENG Ji-ping,WANG Li-na,WANG Li-xiang,REN Xiao-hui,ZHANG Meng-ye,XIA Wen,CUI Xing. [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2006, 44(5): 467 -470 .
[10] SHU Ya,QI Feng. Jaw thrust device (JTD) on obesity patients for maintaining the airway patency during general anesthesia induction[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(10): 1072 -1074 .
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd